“Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults A Randomized Trial Daily administration of MK-677 significantly increased mmol/L (5 mg/dL) in the MK-677 group (P 0.015), and growth hormone and insulin-like growth factor I levels insulin sensitivity decreased. The most frequent side effects to those of healthy young adults without serious adverse were an increase in appetite that subsided in a few months effects. Mean fat-free mass decreased in the placebo group and transient, mild lower-extremity edema and muscle but increased in the MK-677 group (change, 0.5 kg [95% pain. Low-density lipoprotein cholesterol levels decreased CI, 1.1 to 0.2 kg] vs. 1.1 kg [CI,0.7 to 1.5 kgl, in the MK-677 group relative to baseline values (change, respectively; P 0.001), as did body cell mass, as reflected by 0.14 mmol/L [CI,0.27 to 0.01 mmol/L]; 5.4 mg/dL [CI, intracellular water (change, 1.0 kg [CI, 2.1 to 0.2 kg] vs. 0.8 10.4 to 0.4 mg/ dL]; P 0.026); no differences between the kg [CI, 0.1 to 1.6 kg], respectively; P 0.021). No groups were observed in total or high-density lipoprotein significant differences were observed in abdominal visceral cholesterol levels. Cortisol levels increased 47 nmol/L (CI, fat or total fat mass; however, the average increase in limb 28 to 71 nmol/L (1.7 g/dL [CI, 1.0 to 2.6 g/dL]) in MKfat was greater in the MK-677 group than the placebo 677 recipients (P 0.020). Changes in bone mineral density group (1.1 kg vs.0.24 kg; P 0.001). Body weight increased consistent with increased bone remodeling occurred in 0.8 kg (CI, 0.3 to 1.8 kg) in the placebo group and 2.7 kg MK-677 recipients. Increased fat-free mass did not result (CI, 2.0 to 3.5 kg) in the MK-677 group (P 0.003). in changes in strength or function. Two-year exploratory Fasting blood glucose level increased an average of 0.3 analyses confirmed the 1-year results. Nass, Ralf et al. “”Effects of an oral ghrelin mimetic on body composition and clinical”